Dr. Reddy's Q4 & Full Year FY25 Financial Results
HYDERABAD, India--(BUSINESS WIRE)--May 09, 2025--
Dr. Reddy's Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter and year ended March 31, 2025. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS).
Q4FY25 FY25
Revenues 85,060 Mn 325,535 Mn
[Up: 20% YoY^; 2% QoQ] [Up: 17% YoY^]
Gross Margin 55.6% 58.5%
[Q4FY24: 58.6%; Q3FY25: [FY24: 58.6%]
58.7%]
SG&A Expenses 24,055 Mn 93,870 Mn
[Up: 17% YoY; Flat QoQ] [Up: 22% YoY]
R&D Expenses 7,258 Mn 27,380 Mn
[8.5% of Revenues] [8.4% of Revenues]
EBITDA 24,749 Mn 92,133 Mn
[29.1% of Revenues] [28.3% of Revenues]
Profit before Tax 20,054* Mn 76,784* Mn
[Up: 25% YoY; 7% QoQ] [Up: 7% YoY]
Profit after Tax 15,939 Mn 56,544 Mn
attributable to Equity [Up: 22% YoY; 13% QoQ] [Up: 2% YoY]
Holders
^Includes Revenues from the acquired Consumer Healthcare business in
Nicotine Replacement Therapy ('NRT') of 5,971 Mn for Q4FY25 and 12,020 Mn
for FY25. Underlying growth excluding NRT business is 12% YoY and 2% QoQ
for Q4FY25 and 12% YoY for FY25. *Includes Profit before Tax from the
recently acquired NRT business of 888 Mn for Q4FY25 and 1,011 Mn (net of
acquisition related expenses) for FY25.
Commenting on the results, Co-Chairman & MD, G V Prasad said: "We achieved double-digit growth across our businesses, driven by successful product launches, increased revenues from key products in the U.S. and the integration of the acquired NRT business. We will continue to strengthen and grow our core businesses through portfolio management and operational excellence, while pursuing strategic partnerships and inorganic growth opportunities."
All amounts in millions, except EPS
All US dollar amounts based on convenience translation rate of 1 USD = 85.43
Dr. Reddy's Laboratories Limited & Subsidiaries
Revenue Mix by Segment for the quarter
YoY QoQ
Particulars Q4FY25 Q4FY24 Gr % Q3FY25 Gr%
( ) ( ) ( )
Global Generics 75,365 61,191 23 73,753 2
North America 35,586 32,626 9 33,834 5
Europe* 12,750 5,208 145 12,096 5
India 13,047 11,265 16 13,464 (3)
Emerging Markets 13,981 12,091 16 14,358 (3)
Pharmaceutical Services and Active
Ingredients (PSAI) 9,563 8,219 16 8,219 16
Others 132 1,420 (91) 1,614 (92)
Total 85,060 70,830 20 83,586 2
Revenue Mix by Segment for year
YoY
Particulars FY25 FY24 Gr%
( ) ( )
Global Generics 289,552 245,453 18
North America 145,164 129,895 12
Europe* 35,882 20,511 75
India 53,734 46,407 16
Emerging Markets 54,771 48,640 13
PSAI 33,846 29,801 14
Others 2,137 3,910 (45)
Total 325,535 279,164 17
*Includes Revenues from the acquired NRT business of 5,971 Mn for Q4FY25 and
12,020 Mn for FY25. Underlying growth for Europe excluding NRT business is 30%
YoY and 12% QoQ for Q4FY25 and 16% YoY for FY25.
Consolidated Income Statement for the quarter
YoY
Gr QoQ
Particulars Q4FY25 Q4FY24 % Q3FY25 Gr%
($) ( ) ($) ( ) ($) ( )
Revenues* 996 85,060 829 70,830 20 978 83,586 2
Cost of Revenues 442 37,797 344 29,347 29 404 34,534 9
Gross Profit 553 47,263 486 41,483 14 574 49,052 (4)
% of Revenues 55.6% 58.6% 58.7%
Selling, General &
Administrative
Expenses 282 24,055 240 20,476 17 282 24,117 (0)
% of Revenues 28.3% 28.9% 28.9%
Research &
Development
Expenses 85 7,258 80 6,877 6 78 6,658 9
% of Revenues 8.5% 9.7% 8.0%
Impairment of
Non-Current
Assets, net 9 768 (2) (173) (0) (4)
Other
(Income)/Expense,
net (29) (2465) (8) (656) 276 (5) (439) 462
Results from
Operating
Activities 207 17,647 175 14,959 18 219 18,720 (6)
Finance
(Income)/Expense,
net (28) (2352) (12) (1022) 130 0 20
Share of Profit of
Equity Accounted
Investees, net of
tax (1) (55) (0) (35) 57 (0) (42) 31
Profit before
Income Tax 235 20,054(#) 187 16,016 25 219 18,742(#) 7
% of Revenues 23.6% 22.6% 22.4%
Income Tax Expense 49 4,181 34 2,946 42 55 4,704 (11)
Profit for the
Period 186 15,873 153 13,070 21 164 14,038 13
% of Revenues 18.7% 18.5% 16.8%
Attributable to
Equity holders of
the parent
company 187 15,939 153 13,070 22 165 14,133 13
Attributable to
Non-controlling
interests (1) (66) - - - (1) (95) (31)
Diluted Earnings
per Share (EPS) 0.22 19.11 0.18^ 15.7^ 22 0.20 16.9 13
*Includes Revenues of 5,971 Mn from the acquired NRT business. Underlying
growth excluding NRT business is 12% YoY and 2% QoQ.
^Historical numbers re-casted basis the increased number of shares post share
split.
(#) Includes Profit before Tax of 888 Mn from the acquired NRT business.
Earnings before Interest, Tax, Depreciation & Amortization (EBITDA)
Computation for the quarter
Particulars Q4FY25 Q4FY24 Q3FY25
($) ( ) ($) ( ) ($) ( )
Profit before Income Tax 235 20,054 187 16,016 219 18,742
Interest (Income) / Expense,
net* (7) (627) (10) (835) (6) (475)
Depreciation 31 2,636 28 2,421 32 2,733
Amortization 22 1,919 15 1,291 23 1,986
Impairment 9 768 (2) (173) (0) (4)
EBITDA 290 24,749 219 18,720 269 22,982
% of Revenues 29.1% 26.4% 27.5%
*Includes income from Investment
Consolidated Income Statement for the full year
YoY
Particulars FY25 FY24 Gr %
($) ( ) ($) ( )
Revenues* 3,811 325,535 3,268 279,164 17
Cost of Revenues 1,581 135,107 1,353 115,557 17
Gross Profit 2,229 190,428 1,915 163,607 16
% of Revenues 58.5% 58.6%
Selling, General & Administrative
Expenses 1,099 93,870 904 77,201 22
% of Revenues 28.8% 27.7%
Research & Development Expenses 320 27,380 268 22,873 20
% of Revenues 8.4% 8.2%
Impairment of Non-Current Assets, net 20 1,693 0.04 3 56,333
Other (Income)/Expense, net (51) (4,358) (49) (4,199) 4
Results from Operating Activities 841 71,843 793 67,729 6
Finance (Income)/Expense, net (55) (4,724) (47) (3,994) 18
Share of Profit of Equity Accounted
Investees, net of tax (3) (217) (2) (147) 48
Profit before Income Tax(#) 899 76,784 841 71,870 7
% of Revenues 23.6% 25.7%
Income Tax Expense 229 19,539 189 16,186 21
Profit for the Period 670 57,245 652 55,684 3
% of Revenues 17.6% 19.9%
Attributable to Equity holders of the
parent company 662 56,544 652 55,684 2
Attributable to Non-controlling
interests 8 701 - - -
Diluted Earnings per Share (EPS) 0.79 67.8 0.78^ 66.8 1
*Includes Revenues of 12,020 Mn from the acquired NRT business. Underlying
growth excluding NRT business is 12% YoY. (#) Includes Profit before Income
Tax of 1,011 Mn (net of acquisition related expenses) from the acquired NRT
business. ^Historical numbers re-casted basis the increased number of shares
post share split.
EBITDA Computation for the year
Particulars FY25 FY24
($) ( ) ($) ( )
Profit before Income Tax 899 76,784 841 71,870
Interest (Income) / Expense, net* (40) (3,402) (44) (3,716)
Depreciation 123 10,505 112 9,576
Amortization 77 6,553 62 5,280
Impairment 20 1,693 0 3
EBITDA 1,078 92,133 972 83,013
% of Revenues 28.3% 29.7%
*Includes income from Investment
Key Balance Sheet Items
As on 31(st) Mar As on 31(st) Dec As on 31(st) Mar
Particulars 2025 2024 2024
($) ( ) ($) ( ) ($) ( )
Cash and Cash
Equivalents and Other
Investments 799 68,299 751 64,198 966 82,529
Trade Receivables 1,058 90,420 1,079 92,212 940 80,298
Inventories 832 71,085 838 71,630 744 63,552
Property, Plant, and
Equipment 1,144 97,761 1,089 93,053 900 76,886
Goodwill and Other
Intangible Assets 1,271 108,613 1,227 104,780 482 41,204
Loans and Borrowings
(Current &
Non-Current) 547 46,766 598 51,085 234 20,020
Trade Payables 416 35,523 422 36,022 362 30,919
Equity 3,947 337,166 3,764 321,565 3,284 280,550
Key Business Highlights for Q4FY25
-- Partnered with Shanghai Henlius Biotech, Inc. to commercialize HLX15
(daratumumab biosimilar) in the U.S. and Europe
-- Partnered with Bio-Thera Solutions for BAT2206 (ustekinumab biosimilar)
for Southeast Asia and Colombia as well as BAT2506 (golimumab biosimilar)
for Southeast Asia
-- Received Biologics License Application $(BLA.AU)$ acceptance for AVT03
(denosumab biosimilar) developed by our partner, Alvotech for the U.S.
market
-- Received 'Marketing Authorisation' for rituximab biosimilar from UK MHRA
-- Participated in India's 'Jan Aushadi' program with one of our products to
provide accessible generic medicines to the public
ESG Highlights for Q4FY25
-- Recognized in the 'Leadership category' on the Indian Corporate
Governance Scorecard 2024 assessment undertaken by Institutional Investor
Advisory Services (IiAS)
-- Achieved an improved 'EcoVadis' score of 73, placing us among the top 15%
of companies assessed globally
-- Won the 'Climate Action Program 2.0deg Award' in the highest 'Resilient'
category in the Light Manufacturing Sector.
-- Received 'Excellence in Rural Health Initiative' award from Economic
Times
Other Updates for Q4FY25
-- Received the Establishment Inspection Report (EIR) following a routine
GMP inspection by the U.S. FDA at our API manufacturing facility (CTO-2)
in Bollaram, Hyderabad. The inspection was classified as Voluntary Action
Initiated (VAI).
-- Completed the divestment of our manufacturing facility in Shreveport,
Louisiana, U.S., to Jaguar Labs Holdings, LLC.
Revenue Analysis
-- Q4 FY25 consolidated revenues stood at 85.1 billion, YoY growth of 20%
and QoQ growth of 2%. Excluding the NRT business, underlying growth was
12% YoY and 2% QoQ. FY25 consolidated revenues reached 325.5 billion, YoY
growth of 17%. Underlying revenue growth, excluding NRT business was 12%
YoY. The performance was driven by contributions from the acquired NRT
business, complemented by steady growth across our core businesses -
Global Generics and Pharmaceutical Services & Active Ingredients (PSAI).
Global Generics (GG)
-- Q4FY25 revenues at 75.4 billion, YoY growth of 23% and QoQ growth of 2%.
Underlying growth excluding NRT business is 13% YoY and 2% QoQ. FY25
revenues at 289.6 billion, a YoY growth of 18%. Underlying YoY growth
excluding NRT business is 13%. Growth was primarily driven by
contributions from the acquired NRT business, higher sales volumes, and
new product launches, partially offset by price erosion in North America
and Europe.
North America
-- Q4FY25 revenues at 35.6 billion, YoY growth of 9% and QoQ growth of 5%.
FY25 revenues at 145.2 billion, YoY growth of 12%. The YoY growth was
primarily driven by new product launches, increased volumes of select key
products, partially offset by price erosion in certain products.
-- During the quarter, we launched seven new products in the U.S. A total of
18 products were launched during the fiscal year.
-- We filed ten new Abbreviated New Drug Applications (ANDAs) with the USFDA
during the fiscal year. As of March 31, 2025, 76 generic filings were
pending approval from the USFDA. These comprise of 73 ANDAs and three New
Drug Applications (NDAs) filed under Section 505(b)(2) route of the US
Federal Food, Drug, and Cosmetic Act. Of the 73 ANDAs, 44 are Paragraph
IV applications, and we believe that 20 of these have a 'First to File'
status.
Europe
-- Q4FY25 revenues at 12.8 billion, YoY growth of 145% and QoQ growth of 5%.
This includes revenues from the acquired NRT business. Underlying growth
excluding NRT business is 30% YoY and 12% QoQ.
-- NRT at 6.0 billion, QoQ decline of 1%
-- Germany at 3.6 billion, YoY growth of 26% and QoQ growth of 7%
-- UK at 2.2 billion, YoY growth of 43% and QoQ growth of 14%
-- Rest of Europe at 1.1 billion, YoY growth of 20% and QoQ growth of
27%
-- FY25 revenues at 35.9 billion, YoY growth of 75%. Underlying YoY growth
excluding NRT business is 16%.
-- NRT at 12.0 billion
-- Germany at 12.9 billion, YoY growth of 21%
-- UK at 7.3 billion, YoY growth of 15%
-- Rest of Europe at 3.7 billion, YoY growth of 4%
-- The growth in Europe was primarily on account of revenues from the
acquired NRT business, momentum in the base business volumes and new
product launches, partly offset by price erosion.
-- During the quarter, we launched 10 new products in the region, taking the
full year total to 39.
India
-- Q4FY25 revenues at 13.0 billion, YoY growth of 16% and QoQ decline of 3%.
-- FY25 revenues at 53.7 billion, YoY growth of 16%. Growth was driven by
revenues from the vaccine portfolio in-licensed from Sanofi India,
successful new product launches and price increases, partially offset by
lower volumes.
-- As per IQVIA, our IPM rank was maintained at 10. The total no. of new
product launches in India is 23 for the full fiscal.
Emerging Markets
-- Q4FY25 revenues at 14.0 billion, YoY growth of 16% and QoQ decline of 3%.
YoY growth is largely attributable to new product launches across various
countries and higher volumes for existing products. QoQ decline is
largely due to lower volumes. -Revenues from Russia at 6.5 billion, YoY
growth of 31% and QoQ decline of 7%. YoY growth was largely due to new
product launches and higher volumes. QoQ decline was due to lower sales
volumes and change in product mix. -Revenues from other Commonwealth of
Independent States (CIS) countries and Romania at 2.4 billion, YoY growth
of 13% and QoQ growth of 1%. YoY growth was largely on account of higher
base business volumes. -Revenues from Rest of World (RoW) territories at
5.0 billion, growth of 1% YoY and QoQ. Contribution from new product
launches was partially offset by lower base business volumes and price
erosion in certain countries.
-- FY25 revenues at 54.8 billion, YoY growth of 13%. The growth is mainly
attributable to higher base business volumes, new launches, partly offset
by adverse forex. -Revenues from Russia at 26.0 billion, YoY growth of
16%. The growth was largely on account of improved base business volumes,
revenues from new launches and price increases in certain brands.
-Revenues from other CIS countries and Romania at 8.9 billion, YoY growth
of 3%. -Revenues from RoW territories at 19.9 billion, YoY growth of 12%.
The growth is largely due to higher base business volumes and new product
launches, partially offset by price erosion. During Q4FY25, we launched
26 new products across countries, taking the annual total to 85.
Pharmaceutical Services and Active Ingredients (PSAI)
-- Q4FY25 revenues at 9.6 billion, growth of 16% YoY and QoQ.
-- FY25 revenues at 33.8 billion, with a growth of 14% YoY. Growth was due
to increase in API volumes, new launches of API products, partially
offset by lower prices. This was further augmented by growth in the
pharmaceutical services business. During the quarter, we filed 52 Drug
Master Files (DMFs) globally, taking the annual count to 111.
Income Statement Highlights:
Gross Margin
-- Q4FY25 at 55.6% (GG: 59.3%, PSAI: 26.3%), a YoY decline of 300 basis
points (bps) and a QoQ decline of 312 bps. YoY decline was attributed to
higher price erosion in generics, lower manufacturing overhead leverage
and milestone income accrued in the previous year. The sequential decline
was mainly due to lower manufacturing overhead leverage and higher
milestone income recorded in the previous quarter. FY25 at 58.5% (GG:
62.0%, PSAI: 27.1%), a YoY decrease of 11 bps, in line with previous
year.
Selling, General & Administrative (SG&A) Expenses
-- Q4FY25 at 24.1 billion, YoY increase of 17% and flat QoQ. FY25 at 93.9
billion, YoY increase of 22%. The increase was largely driven by higher
investments in sales and marketing to strengthen existing brands and
support new business initiatives, including the expansion of our consumer
healthcare portfolio. It also reflects higher personnel costs from our
growth initiatives and elevated freight rates.
Research & Development (R&D) Expenses
-- Q4FY25 at 7.3 billion. As % to Revenues -- Q4FY25: 8.5% | Q4FY24: 9.7% |
Q3FY25: 8.0%. FY25 at 27.4 billion. As % to Revenues -- FY25: 8.4% |
FY24: 8.2%. R&D investments continued to support our pipeline across
small molecules, biosimilars, complex generics, including peptides, and
novel oncology assets.
Impairment on Non-Current Assets
-- Q4FY25 loss at 0.8 billion compared to a reversal of 0.2 billion in
Q4FY24. The impairment charge relates to certain product-related
intangibles from the Mayne portfolio and other assets within our global
generics business in India and Europe, impacted by adverse market
conditions. FY25 loss at 1.7 billion as compared to 0.003 billion in
FY24. The impairment of intangibles pertains to product-related assets in
India, Europe, and North America, driven by procurement constraints and
challenging market conditions.
Net Finance Income/Expense
-- Q4FY25 income at 2.4 billion compared to expense of 1.0 billion in
Q4FY24. FY25 income at 4.7 billion as compared to 4.0 billion in FY24.
The increase was largely on account of higher foreign currency exchange
gain.
Profit before Tax
-- Q4FY25 at 20.1 billion, a YoY growth of 25% and a QoQ growth of 7%. As %
to Revenues -- Q4FY25: 23.6% | Q4FY24: 22.6% | Q3FY25: 22.4%. FY25 at
76.8 billion, a YoY growth of 7%. As % to Revenues --FY25: 23.6% | FY24:
25.7%. Profit before tax ('PBT') includes 888 Mn in Q4 and 1,011 Mn in
FY25 from the recently acquired NRT business.
Income Tax
-- Q4FY25 at 4.2 billion. As % to PBT -- Q4FY25: 20.8% | Q4FY24: 18.4% |
Q3FY25: 25.1%. The effective tax rate ('ETR') for the quarter is lower
due to: - Reversal of previously recognized tax provision pertaining to
prior years. - Following the sale of membership interest in one of the
group entities, the cumulative foreign exchange gain has been transferred
from the foreign currency translation reserve ('FCTR') to the income
statement. Such FCTR is not subject to taxation. FY25 at 19.5 billion. As
% to PBT -- FY25: 25.4% | FY24: 22.5%. The ETR for the full year is
higher, primarily due to the reversal of a previously recognized deferred
tax asset related to land indexation and recognition of a previously
unrecognized deferred tax asset on operating tax losses.
Profit attributable to Equity Holders of Parent Company
-- Q4FY25 at 15.9 billion, a YoY growth of 22% and a QoQ growth of 13%. As %
to Revenues -- Q4FY25: 18.7% | Q4FY24: 18.5% | Q3FY25: 16.9%. FY25 at
56.5 billion, a YoY growth of 2%. As % to Revenues -- FY25: 17.4% | FY24:
19.9%.
Diluted Earnings per Share (EPS)
-- Q4FY25 is 19.11. FY25 is 67.78.
Other Financial Highlights:
EBITDA
-- Q4FY25 at 24.8 billion, YoY growth of 32% and QoQ growth of 8%. As % to
Revenues -- Q4FY25: 29.1% | Q4FY24: 26.4% | Q3FY25: 27.5%.
-- FY25 at 92.1 billion, a YoY growth of 11%. As % to Revenues -- FY25:
28.3% | FY24: 29.7%.
Others:
-- Operating Working Capital: As on 31st March 2025 at 125.9 billion. -- Capital Expenditure: Q4FY25 at 7.7 billion. FY25 at 27.0 billion. -- Free Cash Flow: Q4FY25 at 11.1 billion. FY25 at 13.3 billion. -- Net Cash Surplus: As on 31st March 2025 at 24.5 billion -- Net Debt to Equity: As on 31st March 2025 is (0.07) -- Return on Capital Employed (RoCE): FY25 at 27.7%
About key metrics and non-GAAP Financial Measures
This press release contains non-GAAP financial measures within the meaning of Regulation G and Item 10(e) of Regulation S-K. Such non-GAAP financial measures are measures of our historical performance, financial position or cash flows that are adjusted to exclude or include amounts from the most directly comparable financial measure calculated and presented in accordance with IFRS.
The presentation of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with IFRS. Our non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles. These measures may be different from non-GAAP financial measures used by other companies, limiting their usefulness for comparison purposes.
We believe these non-GAAP financial measures provide investors with useful supplemental information about the financial performance of our business, enable comparison of financial results between periods where certain items may vary independent of business performance, and allow for greater transparency with respect to key metrics used by management in operating our business.
For more information on our non-GAAP financial measures and a reconciliation of GAAP to non-GAAP measures, please refer to "Reconciliation of GAAP to Non-GAAP Results" table in this press release.
All amounts in millions, except EPS
Reconciliation of GAAP Measures to Non-GAAP Measures
Operating Working Capital
Particulars As on 31(st) Mar 2025
( )
Inventories 71,085
Trade Receivables 90,420
Less:
Trade Payables (35,523)
Operating Working Capital 125,982
Cash Flow
Three months ended 31(st) Year
Particulars Mar 2025 ended 31(st) Mar 2025
( )
Net cash generated from
operating activities 26,578 66,421
Less:
Taxes (4,583) (19,993)
Investments in
Property, Plant &
Equipment and
intangibles (10,942) (33,154)
Free Cash Flow before
Acquisitions 11,053 13,274
Less:
Acquisitions related
pay-out (1,655) (53,096)
Cash Flow 9,399 (39,822)
Net Cash Surplus and Debt to Equity
Particulars As on 31(st) Mar 2025
( )
Cash and Cash Equivalents 14,654
Investments 53,645
Short-term Borrowings (38,902)
Long-term Borrowings, Non-Current (7,864)
Less:
Restricted Cash Balance -- Unclaimed Dividend and
others 441
Lease liabilities (included in Long-term Borrowings,
Non-Current) (4,921)
Equity Investments (Included in Investments) 1,478
Net Cash Surplus 24,535
Equity 337,166
Net Debt/Equity (0.07)
Computation of RoCE
Particulars As on 31(st) Mar 2025
( )
Profit before Tax 76,784
Less:
Interest and Investment Income (Excluding forex
gain/loss) (3,402)
Earnings Before Interest and taxes [A] 73,382
Average Capital Employed [B] 265,345
Return on Capital Employed (A/B) (Ratio) 27.7%
Computation of Capital Employed:
Particulars As on
Mar 31, 2025 Mar 31, 2024
Property Plant and Equipment 97,761 76,886
Intangibles 96,803 36,951
Goodwill 11,810 4,253
Investment in Equity Accounted Associates 4,811 4,196
Other Current Assets 30,142 22,560
Other Investments 10,391 1,059
Other Non-Current Assets 972 1,632
Inventories 71,085 63,552
Trade Receivables 90,420 80,298
Derivative Financial Instruments (729) (299)
Less:
Other Liabilities 48,788 46,866
Provisions 6,324 5,444
Trade payables 35,523 30,919
Operating Capital Employed 322,831 207,859 Average Capital Employed 265,345
Computation of EBITDA
Refer page no. 3 & 4.
Earnings Call Details
The management of the Company will host an Earnings call to discuss the Company's financial performance and answer any questions from the participants.
Date: May 9, 2025
Time: 19:30 pm IST | 10:00 am ET
Conference Joining Information
Option 1: Pre-register with the below link and join without waiting for the operator
https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=7115642&l
inkSecurityString=3276024124
Option 2: Join through below Dial-In Numbers
Universal Access Number: +91 22 6280 1219
+91 22 7115 8120
International Toll-Free Number: USA: 1 866 746 2133
UK: 0 808 101 1573
Singapore: 800 101 2045
Hong Kong: 800 964 448
No password/pin number is necessary to dial in to any of the above numbers. The operator will provide instructions on asking questions before and during the call.
Play Back will be available after the earnings call, till May 16(th) , 2025. For play back, dial in phone No: +91 22 7194 5757, and playback code is 59320#.
Audio Link and Transcript will be available on the Company's website: www.drreddys.com
About Dr. Reddy's: Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of 'Good Health Can't Wait', we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include -- USA, India, Russia & CIS countries, China, Brazil, and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance.
For more information, log on to: www.drreddys.com.
Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates, persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers', products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report on Form 20-F for the year ended March 31, 2024 and quarterly financial statements filed in Form 6-K with the US SEC for the quarter ended June 30, 2024, September 30, 2024, December 31, 2024 and our other filings with US SEC. The company assumes no obligation to update any information contained herein.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250509262055/en/
CONTACT: INVESTOR RELATIONS
RICHA PERIWAL richaperiwal@drreddys.com
AISHWARYA SITHARAM aishwaryasitharam@drreddys.com
MEDIA RELATIONS
PRIYA K
priyak@drreddys.com
(END) Dow Jones Newswires
May 09, 2025 14:53 ET (18:53 GMT)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.